The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes, as described in a Special Supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. (http://www.liebertpub.com). The issue is available free online (http://www.liebertpub.com/dia).
“Improved delivery devices for insulin treatment have increased patient compliance and acceptance of an intensive insulin strategy,” which can result in significant reductions in long-term complications associated with poorly controlled type 1 and type 2 diabetes, says Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver, in his Editorial entitled “Impact of Insulin Delivery Devices in Diabetes Care.”
The development of automated glucose-controlled insulin infusion systems that combine the advantages of continuous glucose measurement with intravenous insulin infusion pumps “is likely to explode over the next several years,” predicts Jay Skyler, MD, Professor of Medicine, Pediatrics, and Psychology at the University of Miami Miller School of Medicine (Florida), in the article, “Continuous Subcutaneous Insulin Infusion??es Technology & Therapeutics is a peer-reviewed journal published monthly that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Technologies include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed online (http://www.liebertpub.com/dia).
Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Metabolic Syndrome and Related Disorders, Obesity and Weight Management, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 60 journals, books, and newsmagazines is available at our website (http://www.liebertpub.com).
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101
Contact: Vicki Cohn
Mary Ann Liebert, Inc./Genetic Engineering News